• Biomolecules & Therapeutics
• /
• 제29권4호
• /
• pp.445-451
• /
• 2021

Salicylamide, a non-steroidal anti-inflammatory drug (NSAID), is used as an analgesic and antipyretic agent. We have previously shown that several NSAIDs have anti-melanogenic properties in B16F1 melanoma cells. In contrast, we have found that salicylamide enhances melanin contents in B16F1 melanoma cells; however, the underlying mechanism is not known. Therefore, we investigated the mechanism through which salicylamide stimulates melanogenesis. Interestingly, salicylamide enhanced diphenolase activity in a cell-free assay. Western blotting and real-time RT-PCR revealed that salicylamide increased tyrosinase expression via transcriptional activation of the Mitf gene. Together, our results indicate that salicylamide could be used as an anti-hypopigmentation agent for skin and/or hair.

• Journal of Pharmaceutical Investigation
• /
• 제1권1호
• /
• pp.30-33
• /
• 1971

Comparative studies were made on the analgesic effect of salicylamide, used individually and combined with parasympatholytics (propantheline and atropine) and antihistaminics (tripelennamine, diphenhydramine) as regards the analgesic effect (in thermal contact method) were examined by its oral administration with each combined drug to mouse (three assumption cross-over test), and the following effects were found. 1. The increasing order of the parasympatholytics to the analgesic effect of salicylamide is as follows: propantheline>atropine. 2. The increasing order of the antihistaminics to the analgesic effect of salicylamide is as follows: chlorpheniramine>diphenhdramine>tri pelennamine. In the ratio '1 : 1' salicylamide to parasympatholytics and antihistaminics, the analgesic effect of salicylamide was more increase than the other ratio in this study.

• Journal of Pharmaceutical Investigation
• /
• 제5권4호
• /
• pp.32-37
• /
• 1975

The intentional test of the clinical test on the mouse, which are orally administered salicylamide combined with chlorpheniramine maleate were made by writhing syndrome method of 0.7% acetic acid-saline solution and following effects were found. 1) The cross-over test of writhing syndrome method have intention in case of three days rest after the first examination. 2) The most active rate of salicylamide by administration combined with chlorpheniramine maleate is salicylamide 20mg/kg: chlorpheniramine maleate 20mg/kg (1:1) 3) The most active range of chlorpheniramine maleate used for assistant action of salicylamide is $15mg/kg{\sim}20mg/kg$

• Journal of Pharmaceutical Investigation
• /
• 제1권1호
• /
• pp.78-84
• /
• 1971

The comparative studies were made on Salicylamide, used individually and compounded with antihistaminics as regards. (1) the absorption rate through isolated rat small intestine (in vitro) (2) the absorption rate through rat small intestine (in vivo), and the following effects were found. 1. The Absorption velosity of 2 m Mole gm. of salicylamide in the small intestine were decreased, when the agents compounded with tripelennamine indicating the greatest absorption inhibition in the case of m Mole gm. of tripelennamine. 2. The Absorption velosity of 2m Mole gm. of salicylamide in the small intestine were decreased, when the agents compounded with diphenhydramine indicating the greatest absorption inhibition in the case of 2m Mole gm. of diphenhydramine. 3. The Absorption velosity of 2m Mole gm. of salicylamide in the small intestine were increased, when the agents compounded with chlorpheniramine indicating the greatest absorption augmentation in the case of 0.2m Mole gm. of chlorpheniramine.

• Archives of Pharmacal Research
• /
• 제24권3호
• /
• pp.180-189
• /
• 2001

A new series of pyridazine, pyrazoles, pyrazolidine-3,5-dione, Semicarbazide, thiosemicarbazides, hydantoin, thiohydantoins, 1,2,4-triazoles, S-triazolo[3,4-b]-1,3,4-thiadiazoles incorporated indirectly into salicylamide moiety at position 2 were synthesized. Also the synthesis of novel series of 3-salicylamido-2-hydroxypropyl-amino derivatives were prepared. Several of these compounds were screened for antiinflammatory, analgesic, antipyretic and ulcerogenic activities.

• 약학회지
• /
• 제20권3호
• /
• pp.130-137
• /
• 1976

Specific association phenomena of riboflayin-2',3',4',5',- tetraacetate and salicylic acid derivatives, such as salicylic acid, aspirin and salicylamide have been measured by infrared and fluorescence spectroscopy. Salicylic acid and riboflavin tetraacetate oxyl group of the former. Asprin and riboflavin tetraacetate form the 1:1 cyclic hydrogen bonded dimer by the same mode. Salicylamide froms the 1:1 cyclic hydrogen bonded dimer with riboflavin tetraacetate by using its amide group and carbonyl group. Salicylic acid derivatives are effective quenchers of the fluorescence of riboflavin tetraacetate. It is appeared that salifylamide is the strongest quencher among them. The quenching effect is attributed to the formation of association dimer.

• Archives of Pharmacal Research
• /
• 제8권3호
• /
• pp.109-117
• /
• 1985

The interaction of salicylic acid (S. A.), salicylamide (S,M) with nucleic acid base derivatives such as 9-ethyl adenine (A), 1-cyclohexyl uracil (U), 2', 3'-benzylidine-5' trityl-cytidine (C), gaunosine-2', 3', 5'-isobutylate (G) has been spectroscopically investigated to determine the binding mechanism. NMR and IR spectra were measured in nonpolar solvents. The association constant K of the formation of complex was calculated from the IR spectra. Compounds S. A. and A form a 1:1 or 1:2 cyclic hydrogen-bonded complex depending on the sample concentration. Compounds S. A. and U form a 1:1 or 1:2 hydrogen-bonded complex on the sample concentration. Compounds S. A. and C form a 2:1 hydrogen-bonded complex at low concentration (0.0016M). Compound S. A. binds compound G, but its binding does not completely break the self-association of compound G, Compound S. M. binds compounds A. U. C. G. very weakly.

• Biomolecules & Therapeutics
• /
• 제3권1호
• /
• pp.85-90
• /
• 1995

Phenol, acetaminophen (AA) and salicylamide are all known to be sulfated in rats and mice. We have previously demonstrated that capacity-limited sulfation of xenobiotics in rats is due to the reduced availability of hepatic 3'-phosphoadenosine 5'-phosphosulfate (PAPS), the cosubstrate for sulfation, which in turn is limited by the availability of its precursor, inorganic sulfate. Because species differences have been reported in the extent of sulfation, this study was conducted to determine whether these xenobiotics lower hepatic PAPS and sulfate in ICR mice. All three substrates decreased serum sulfate concentrations in a dose- and time-dependent manner. However, contrary to the observations in rats, phenol markedly increased hepatic PAPS concentrations in a dose-dependent manner, 1 hr after ip injection of 0∼4 mmol/kg. Following ip injection of 4 mmol/kg phenol, hepatic PAPS concentraions were enhanced 2∼3 fold, 0.5-2 hr after dosing and returned to control values 3 hr after dosing, whereas AA and salicylamide had little effect on hepatic PAPS concentraions. In summary, these studies demonstrate that phenol markedly enhances hepatic PAPS concentrations in mice, whereas hepatic PAPS levels are not affected by AA and salicylamide. Our data suggest that 1) hepatic sulfation for high dosages of xenobiotics in ICR mice is not limited by the availability of cosubstrate and 2) there are significant species differences in the regulation of PAPS between rats and mice.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1994년도 춘계학술대회 and 제3회 신약개발 연구발표회
• /
• pp.337-337
• /
• 1994

Phenol, acetaminophen(AA) and salicylamide are all known to be sulfated in rats and mioe. We have previously demonstrated that capacity-limited sulfation of xenobiotics in rats is due to the reduced availability of hepatic PAPS, the co-substrate for sulfation, which in turn is limited by the availability of its precursor, inorganic sulfate. Because species differences have been reported in the extent of sulfation, this study was conducted to determine whether these xenobiotics lower hepatic PAPS and sulfate in ICR mice. All three substrates decreased serum sulfate concentrations in a dose-and time-dependent manner. However. contrary to the observations in rats, phenol markedly increased hepatic PAPS concentraions in a dose-dependent manner, 1 hr after ip injection of 0-4 mmol/kg. Following ip injection of 2 or4 mmol/kg phenol, hepatic PAPS concentraions were enhanced 2-3 fold, 0.52 hr arter dosing and returned to control values 3 hr after dosing, whereas AA and salicylamide had little effect on hepatic PAPS concentrations. In summary. these studies demonstrate that phenol markedly enhances hepatic PAPS concentrations in mice, whereas hepatic PAPS levels are not affected by AA and salicylamide. Our data suggest that 1) hepatic sulfation for high dosages of xenobiotics in ICR mice is not limiod by the availability of co-substrate, and 2) there are significant species differences in the regulation of PAPS between rats and mice.

• Journal of Pharmaceutical Investigation
• /
• 제10권1호
• /
• pp.4-12
• /
• 1980

The studies of the compounding analgestic antipyretics were examined by the converted Koster's method (mice) and the converted Mac Donald's method (mice) induced on the three assumption crossover test. And the following results were found. 1. The same effect of the writhing inhibition in this compounding antipyretic dosage by it's oral administration is as follows. Aminopyrine 100mg/kg. (standard), aminopyrine 50mg/kg compounding with chlorpheniramine maleate 2mg/kg., compounding with diphenhydramine hydrochloride 8mg/kg., compounding with atropine sulfate 0.2mg/kg., or compounding with scopolamine hydrobromide 0.2mg/kg. And aspirin80mg/kg., Salicylamide 90mg/kg., sulpyrine 60mg/kg., or phenacetin 70mg/kg. compounding with the same dosage of the adjutants above. 2. The elevation-rate of the reaction threshold in this compounding antipyretic dosage by it's oral administration calculate as follows. When the elevation-rate (ER) of aminopyrine (100mg./kg.) is 1.00 (Standard), ER of aminopyrine (50mg./kg.) compounding with chlorpheniramine maleate (2mg./kg.) calculated 1.42, aspirin (80.mg./kg.) compounding with diphenhydramine hydrochloride (80mg./kg.) calculated 1.18, salicylamide (90mg./kg.) compounding with chlorpheniramine maleate (2mg./kg.) calculated 1.15, sulpyrine (60mg./kg.) compounding with chlorpheniramine maleate(2mg./kg.) calculated 1.28, and ER phenacetin (70mg./kg.) compounding with chlorpheniramine maleate (2mg./kg.) calculated 1.19.